Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olimel N12 for Nutritional Status in Hemodialysis Patients
NCT04094038Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2019
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 4 trial of Olimel N12 in protein-energy wasting (PEW), Malnutrition, Sarcopenia, sponsored by Erasmus MC. Started Sep 2019; status: active, not recruiting.
02
Drugs
Olimel N12
03
Conditions
protein-energy wasting (PEW)MalnutritionSarcopenia
Beyond the preview
Go deeper on NCT04094038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094038.